Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jun 2025 According to a Bristol Myers Squibb media release, data from this trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress.
11 Jun 2025 Results published in the Bristol Myers Squibb Media Release
23 Dec 2024 Primary endpoint has been met (Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR 20) response) , according to a Bristol Myers Squibb media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com